pharmjournal-world.com Report : Visit Site


  • Server:nginx/1.14.0...

    The main IP address: 88.99.148.162,Your server United Kingdom,Rochdale ISP:Zen Internet Ltd  TLD:com CountryCode:GB

    The description :"drug development & registration" | the research and production reviewed magazine rus eng +7 (495) 720-42-20 [email protected] -- toggle navigation main the journal about journal issues media r...

    This report updates in 03-Sep-2018

Created Date:2013-07-17
Changed Date:2017-06-26

Technical data of the pharmjournal-world.com


Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host pharmjournal-world.com. Currently, hosted in United Kingdom and its service provider is Zen Internet Ltd .

Latitude: 53.617660522461
Longitude: -2.1552000045776
Country: United Kingdom (GB)
City: Rochdale
Region: England
ISP: Zen Internet Ltd

HTTP Header Analysis


HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.14.0 containing the details of what the browser wants and will accept back from the web server.

Content-Encoding:gzip
Transfer-Encoding:chunked
Set-Cookie:evo179b0h2=m5n29lf5jrd5gehiisenamffb4; path=/, evo179b0h2=m5n29lf5jrd5gehiisenamffb4; path=/; httponly
Vary:Accept-Encoding
Server:nginx/1.14.0
Connection:keep-alive
Cache-Control:private, must-revalidate
Date:Mon, 03 Sep 2018 12:20:28 GMT
P3P:CP="NOI NID ADMa OUR IND UNI COM NAV"
Content-Type:text/html; charset=UTF-8

DNS

soa:dns.fastdns24.com. support.fastvps.ru. 2017050202 10800 3600 604800 86400
ns:dns2.fastdns24.org.
dns3.fastdns24.eu.
dns4.fastdns24.link.
dns.fastdns24.com.
ipv4:IP:88.99.148.162
ASN:24940
OWNER:HETZNER-AS, DE
Country:DE
mx:MX preference = 10, mail exchanger = mail.pharmjournal-world.com.

HtmlToText

"drug development & registration" | the research and production reviewed magazine rus eng +7 (495) 720-42-20 [email protected] -- toggle navigation main the journal about journal issues media registration sertificate editorial board primary sections articles archive rules for authors vacancies for advertisers subscribtion to the journal to glpnews delivery news events publisher contacts international partnership publisher's projects laboratory research testing the safety of immunotherapy in diabetes new class of antibiotic raises hopes for urgently-needed gonorrhoea drug broad scientists show how 1 bad gene takes a toll on 5 vascular diseases u.s. scientists able to alter genes of human embryos could car-t treatments work in glioblastoma? 'switch' in brain of obese people stays on all the time, researchers say microbiome shows copd subtypes preclinical trials one step closer to a zika vaccine for pregnant women a listeria-derived polypeptide promotes in vivo activation of nk cells for antitumor therapy anti-pcsk9 vaccine lowers cholesterol, atherosclerosis in mice protein's ability to induce tumor cell apoptosis may lead to new anticancer drugs yeast genome 2.0 fully coded, one-third uploaded drug combo can regenerate hair cells, may restore hearing loss growth factor shown to protect the retina in early stage diabetes tsri scientists show deep brain stimulation blocks heroin relapse in rats clinical trials novartis takes aim at drug-resistant malaria sepsis: adrenomed receives approval for poc study in patients with early septic shock type 1 diabetes may be halted by experimental immunotherapy kite begins eu trial of car–t therapy tetraphase pharmaceuticals announces positive phase 1 single-ascending dose data for antibiotic pipeline candidates paratek antibiotic hits endpoints in phase 3, teeing up nda effectiveness of a group b outer membrane vesicle meningococcal vaccine against gonorrhoea in new zealand: a retrospective case-control study fda panel backs novartis' pioneering new cancer gene therapy blood test by britain's angle detects ovarian cancer in study four issues per year archive №2 (23) may 2018 contents read №1 (22) february 2018 contents read №1 (18) february 2017 contents read №2 (19) may 2017 contents read №3 (20) august 2017 contents read №4 (21) november 2017 contents read №4 (17) november 2016 contents read №3 (16) august 2016 contents read №2 (15) may 2016 contents read №1 (14) february 2016 contents read №4 (13) november 2015 contents read №3 (12) august 2015 contents read №2 (11) may 2015 contents read №1 (10) february 2015 contents read synopsis №4 (9) november 2014 contents read synopsis №3 (8) august 2014 contents read synopsis №2 (7) may 2014 contents read synopsis №1 (6) february 2014 contents read synopsis №4 (5) november 2013 contents read synopsis №3 (4) august 2013 contents read synopsis №2 (3) may 2013 contents read №1 (2) february 2013 contents read №1 (1) november 2012 contents read 2018 2017 2016 2015 2014 archive 2012 2013 -- main news seminar for specialists in pharmaceutical industry will be hold in april 24 you have no time for advanced training? don’t know what to choose and how to get budgeting? don't miss it! free scientific and practical seminar “drug development and registration: analytical aspects”. fda expands use of az/merck’s lynparza in the us astrazeneca and merck & co’s lynparza will be available to a wider range of patients in the us after regulators expanded the parp inhibitor’s list of approved uses. fda approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia the u.s. food and drug administration today approved besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory b-cell precursor acute lymphoblastic leukemia (all). novartis takes aim at drug-resistant malaria novartis and medicines for malaria venture (mmv) have launched a patient trial for kaf156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. the bioprocess platform software eve® infors ht is now compatible with applikon and sartorius bioreactors the latest version of eve® can integrate with a wide range of third-party bioreactors and equipment from a number of different suppliers, e.g. sartorius dcu, applikon or matlab. the process data is handled by a single, integrated solution, making the eve® bioprocess platform software a truly universal choice for bioprocess projects. nice turns down kidney cancer drugs it is looking unlikely that patients in england and wales with advanced renal cell carcinoma will be getting routine nhs access to eisai’s kisplyx or eusa pharma’s fotivda, after cost regulators issued draft guidelines turning down their use. sepsis: adrenomed receives approval for poc study in patients with early septic shock germany is the first country that has granted full approval to adrenomed to conduct a phase ii study with the monoclonal antibody adrecizumab in patients with early septic shock. within the adr-02 study, 300 patients will be enrolled in germany, belgium, france and the netherlands for proof of safety and efficacy. testing the safety of immunotherapy in diabetes diabetes occurs when the t cells of the immune system destroy beta cells in the pancreas that produce insulin. diabetes researchers have long been interested in using immunotherapy techniques to tamp down this wayward immune activity, but they’ve worried that they’ll accidentally make the disease worse. type 1 diabetes may be halted by experimental immunotherapy an immunotherapy approach for treating type 1 diabetes has been found to be safe for the first time, and seems to stop the condition from getting worse. in the lead-up to paris aids conference, who prequalifies first generic hepatitis c medicine and first hiv self-test who today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis c. the development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. sofosbuvir, 400 mg tablet, is manufactured by mylan laboratories ltd., india. all news » authorities' news fda expands use of az/merck’s lynparza in the us astrazeneca and merck & co’s lynparza will be available to a wider range of patients in the us after regulators expanded the parp inhibitor’s list of approved uses. fda approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia the u.s. food and drug administration today approved besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory b-cell precursor acute lymphoblastic leukemia (all). nice turns down kidney cancer drugs it is looking unlikely that patients in england and wales with advanced renal cell carcinoma will be getting routine nhs access to eisai’s kisplyx or eusa pharma’s fotivda, after cost regulators issued draft guidelines turning down their use. manufacturers' news the bioprocess platform software eve® infors ht is now compatible with applikon and sartorius bioreactors the latest version of eve® can integrate with a wide range of third-party bioreactors and equipment from a number of different suppliers, e.g. sartorius dcu, applikon or matlab. the process data is handled by a single, integrated solution, making the eve® bioprocess platform software a truly universal choice for bioprocess projects. planetary mixer farmalabor for laboratory use planetary mixer 7kg creamix by farmalabor company used for mixing of substances and for homogenization of creams. it is possible to operate with viscous substances, as well as with powders. application: pharmaceutical, chemical, food and cosmetic industry. the leading manufacturer of specialized furniture for laboratories lamo is presenting new line of chairs bimos lamo company designs and manufactures specialized furniture for laboratories for more than 10 years. now lamo

URL analysis for pharmjournal-world.com


http://pharmjournal-world.com/clinical-trials/kite-begins-eu-trial-of-cart-therapy
http://pharmjournal-world.com/manufacturers-news/the-leading-manufacturer-of-specialized-furniture-for-laboratories-lamo-is-presenting-new-line-of-chairs-bimos
http://pharmjournal-world.com/issue/2016/14-february-2016
http://pharmjournal-world.com/issue
http://pharmjournal-world.com/issue/2015/4-13-november-2015
http://pharmjournal-world.com/issue/2015/2-11-may-2015
http://pharmjournal-world.com/issue/2014/2-7-may-2014
http://pharmjournal-world.com/preclinical-trials/geroinovuyu-narkomaniyu-mozhno-kontrolirovat-s-pomoshhyu-elektricheskoj-stimulyacii-golovnogo-mozga
http://pharmjournal-world.com/issue/2013/3-4-august-2013
http://pharmjournal-world.com/issue/2017/3-20-august-2017
http://pharmjournal-world.com/manufacturers-news/planetary-mixer-farmalabor-for-laboratory-use
http://pharmjournal-world.com/authorities-news/in-the-lead-up-to-paris-aids-conference-who
http://pharmjournal-world.com/laboratory-research/new-class-of-antibiotic-raises-hopes-for-urgently-needed-gonorrhoea-drug
http://pharmjournal-world.com/issue/2015/10-february-2015
http://pharmjournal-world.com/clinical-trials/paratek-antibiotic-hits-endpoints-in-phase-3-teeing-up-nda

Whois Information


Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: PHARMJOURNAL-WORLD.COM
Registry Domain ID: 1815658023_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.reg.com
Registrar URL: http://www.reg.ru
Updated Date: 2017-06-26T12:08:42Z
Creation Date: 2013-07-17T07:38:06Z
Registry Expiry Date: 2018-07-17T07:38:06Z
Registrar: REGISTRAR OF DOMAIN NAMES REG.RU LLC
Registrar IANA ID: 1606
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +74955801111
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS.FASTDNS24.COM
Name Server: DNS2.FASTDNS24.ORG
Name Server: DNS3.FASTDNS24.EU
Name Server: DNS4.FASTDNS24.LINK
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-12T18:51:38Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR REGISTRAR OF DOMAIN NAMES REG.RU LLC

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =pharmjournal-world.com

  PORT 43

  TYPE domain

DOMAIN

  NAME pharmjournal-world.com

  CHANGED 2017-06-26

  CREATED 2013-07-17

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  DNS.FASTDNS24.COM 176.31.3.154

  DNS2.FASTDNS24.ORG 178.132.200.29

  DNS3.FASTDNS24.EU 136.243.223.232

  DNS4.FASTDNS24.LINK 5.254.122.130

  REGISTERED yes

Go to top

Mistakes


The following list shows you to spelling mistakes possible of the internet users for the website searched .

  • www.upharmjournal-world.com
  • www.7pharmjournal-world.com
  • www.hpharmjournal-world.com
  • www.kpharmjournal-world.com
  • www.jpharmjournal-world.com
  • www.ipharmjournal-world.com
  • www.8pharmjournal-world.com
  • www.ypharmjournal-world.com
  • www.pharmjournal-worldebc.com
  • www.pharmjournal-worldebc.com
  • www.pharmjournal-world3bc.com
  • www.pharmjournal-worldwbc.com
  • www.pharmjournal-worldsbc.com
  • www.pharmjournal-world#bc.com
  • www.pharmjournal-worlddbc.com
  • www.pharmjournal-worldfbc.com
  • www.pharmjournal-world&bc.com
  • www.pharmjournal-worldrbc.com
  • www.urlw4ebc.com
  • www.pharmjournal-world4bc.com
  • www.pharmjournal-worldc.com
  • www.pharmjournal-worldbc.com
  • www.pharmjournal-worldvc.com
  • www.pharmjournal-worldvbc.com
  • www.pharmjournal-worldvc.com
  • www.pharmjournal-world c.com
  • www.pharmjournal-world bc.com
  • www.pharmjournal-world c.com
  • www.pharmjournal-worldgc.com
  • www.pharmjournal-worldgbc.com
  • www.pharmjournal-worldgc.com
  • www.pharmjournal-worldjc.com
  • www.pharmjournal-worldjbc.com
  • www.pharmjournal-worldjc.com
  • www.pharmjournal-worldnc.com
  • www.pharmjournal-worldnbc.com
  • www.pharmjournal-worldnc.com
  • www.pharmjournal-worldhc.com
  • www.pharmjournal-worldhbc.com
  • www.pharmjournal-worldhc.com
  • www.pharmjournal-world.com
  • www.pharmjournal-worldc.com
  • www.pharmjournal-worldx.com
  • www.pharmjournal-worldxc.com
  • www.pharmjournal-worldx.com
  • www.pharmjournal-worldf.com
  • www.pharmjournal-worldfc.com
  • www.pharmjournal-worldf.com
  • www.pharmjournal-worldv.com
  • www.pharmjournal-worldvc.com
  • www.pharmjournal-worldv.com
  • www.pharmjournal-worldd.com
  • www.pharmjournal-worlddc.com
  • www.pharmjournal-worldd.com
  • www.pharmjournal-worldcb.com
  • www.pharmjournal-worldcom
  • www.pharmjournal-world..com
  • www.pharmjournal-world/com
  • www.pharmjournal-world/.com
  • www.pharmjournal-world./com
  • www.pharmjournal-worldncom
  • www.pharmjournal-worldn.com
  • www.pharmjournal-world.ncom
  • www.pharmjournal-world;com
  • www.pharmjournal-world;.com
  • www.pharmjournal-world.;com
  • www.pharmjournal-worldlcom
  • www.pharmjournal-worldl.com
  • www.pharmjournal-world.lcom
  • www.pharmjournal-world com
  • www.pharmjournal-world .com
  • www.pharmjournal-world. com
  • www.pharmjournal-world,com
  • www.pharmjournal-world,.com
  • www.pharmjournal-world.,com
  • www.pharmjournal-worldmcom
  • www.pharmjournal-worldm.com
  • www.pharmjournal-world.mcom
  • www.pharmjournal-world.ccom
  • www.pharmjournal-world.om
  • www.pharmjournal-world.ccom
  • www.pharmjournal-world.xom
  • www.pharmjournal-world.xcom
  • www.pharmjournal-world.cxom
  • www.pharmjournal-world.fom
  • www.pharmjournal-world.fcom
  • www.pharmjournal-world.cfom
  • www.pharmjournal-world.vom
  • www.pharmjournal-world.vcom
  • www.pharmjournal-world.cvom
  • www.pharmjournal-world.dom
  • www.pharmjournal-world.dcom
  • www.pharmjournal-world.cdom
  • www.pharmjournal-worldc.om
  • www.pharmjournal-world.cm
  • www.pharmjournal-world.coom
  • www.pharmjournal-world.cpm
  • www.pharmjournal-world.cpom
  • www.pharmjournal-world.copm
  • www.pharmjournal-world.cim
  • www.pharmjournal-world.ciom
  • www.pharmjournal-world.coim
  • www.pharmjournal-world.ckm
  • www.pharmjournal-world.ckom
  • www.pharmjournal-world.cokm
  • www.pharmjournal-world.clm
  • www.pharmjournal-world.clom
  • www.pharmjournal-world.colm
  • www.pharmjournal-world.c0m
  • www.pharmjournal-world.c0om
  • www.pharmjournal-world.co0m
  • www.pharmjournal-world.c:m
  • www.pharmjournal-world.c:om
  • www.pharmjournal-world.co:m
  • www.pharmjournal-world.c9m
  • www.pharmjournal-world.c9om
  • www.pharmjournal-world.co9m
  • www.pharmjournal-world.ocm
  • www.pharmjournal-world.co
  • pharmjournal-world.comm
  • www.pharmjournal-world.con
  • www.pharmjournal-world.conm
  • pharmjournal-world.comn
  • www.pharmjournal-world.col
  • www.pharmjournal-world.colm
  • pharmjournal-world.coml
  • www.pharmjournal-world.co
  • www.pharmjournal-world.co m
  • pharmjournal-world.com
  • www.pharmjournal-world.cok
  • www.pharmjournal-world.cokm
  • pharmjournal-world.comk
  • www.pharmjournal-world.co,
  • www.pharmjournal-world.co,m
  • pharmjournal-world.com,
  • www.pharmjournal-world.coj
  • www.pharmjournal-world.cojm
  • pharmjournal-world.comj
  • www.pharmjournal-world.cmo
Show All Mistakes Hide All Mistakes